Trials / Unknown
UnknownNCT05544682
Cefiderocol in the Treatment of Multidrug-resistant Gram-negative Bacilli Infections, a Retrospective Study
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 15 (estimated)
- Sponsor
- University Hospital, Strasbourg, France · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Cefiderocol is a new antibiotic from the siderophore cephalosporin family for which there are few real-life data on its use in the treatment of infections with multidrug-resistant Gram-negative bacilli. The circulation of bacterial strains multi-resistant to antibiotics is important at the Strasbourg University Hospital, so the investigators wish to report their local experience of the 1st uses of Cefiderocol in the treatment of infections with multi-resistant Gram-negative bacilli to antibiotics in order to better clarify the use of this antibiotic (therapeutic indication, method of administration)
Conditions
Timeline
- Start date
- 2022-09-01
- Primary completion
- 2023-12-01
- Completion
- 2023-12-01
- First posted
- 2022-09-16
- Last updated
- 2023-12-19
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT05544682. Inclusion in this directory is not an endorsement.